Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling?

Clinical Colorectal Cancer

Volumn 10, Issue 2, 2011, Pages 73-80

  Kelley, Robin K ^a   Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Gene expression profile; Gene signature; Recurrence; Stage II colon cancer

Indexed keywords

B RAF KINASE; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; LEVAMISOLE; OXALIPLATIN; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER MORPHOLOGY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CLINICAL STUDY; COLON CANCER; COLON OBSTRUCTION; COLON PERFORATION; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA SEQUENCE; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC MARKER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; LYMPH VESSEL; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; PREDICTIVE VALUE; PROGNOSIS; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR BIOPSY;

EID: 79959357339     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.001     Document Type: Review

References (91)

1. Horner MJ, Reis LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; 2009.
2. Cancer in California. 1988-2002. In. December 2005 ed. State of California, Department of Health Services; 2005.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
4. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020-9.
5. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:979-94.
6. Bilimoria KY, Palis B, Stewart AK, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 2008; 51:154-61.
7. Johnson PM, Porter GA, Ricciardi R, et al. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006; 24:3570-5. (Pubitemid 46630528)
8. Wong SL, Ji H, Hollenbeck BK, et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007; 298:2149-54. (Pubitemid 350106653)
9. Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005; 41:272-9. (Pubitemid 40126960)
10. Steinberg SM, Barkin JS, Kaplan RS, et al. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986; 57:1866-70. (Pubitemid 16112004)
11. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299:448-51. (Pubitemid 9011330)
12. Practice Guidelines NCCN. In: Oncology-v.2.2009 Colon Cancer. National Comprehensive Cancer Network, 2009. http://www.nccn.org/professionals/physician- gls/PDF/colon.pdf. Accessed July 10, 2009.
13. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13:2936-43.
14. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51. (Pubitemid 38702845)
15. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26. (Pubitemid 40051905)
16. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-34. (Pubitemid 46622311)
17. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009. (Pubitemid 35461656)
18. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6. (Pubitemid 34130608)
19. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-806. (Pubitemid 41095169)
20. Douillard JY, Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area! Ann Oncol 2005; 16:1853-4. (Pubitemid 41724271)
21. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87.
22. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8. (Pubitemid 20042739)
23. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-56. (Pubitemid 19245114)
24. Wolpin BM, Meyerhardt JA, Mamon HJ, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57:168-85. (Pubitemid 46798625)
25. Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007; 97:1021-7. (Pubitemid 47587021)
26. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-19.
27. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28(1 suppl 1):20-4. (Pubitemid 32173100)
28. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. In: American Society of Clinical Oncology Annual Meeting; 2007; Chicago, IL. J Clin Oncol 2007; 25:2007.
29. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. In: American Society of Clinical Oncology Annual Meeting; 2009; Orlando, FL: J Clin Oncol; 2009.
30. Shankaran V, Wisinski KB, Mulcahy MF, et al. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008; 12:87-98. (Pubitemid 351570864)
31. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9:489-99.
32. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558-61. (Pubitemid 23186645)
33. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57. (Pubitemid 28521189)
34. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609-18. (Pubitemid 46224239)
35. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-32. (Pubitemid 36298000)
36. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007; 13:3221-8. (Pubitemid 46944905)
37. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14:3408-15.
38. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91:1295-303. (Pubitemid 29387571)
39. Hemminki A, Mecklin JP, Jaodie;rvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119:921-8.
40. Jensen SA, Vainer B, Kruhøffer M, et al. Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer 2009; 9:25.
41. Lanza G, Gafà R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24:2359-67. (Pubitemid 46630668)
42. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57. (Pubitemid 36859476)
43. Sargent DJ, Marsoni SN, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. In: American Society of Clinical Oncology Annual Meeting; 2008; Chicago. J Clin Oncol 2008;26:abstr 4008.
44. Sinicrope FA, Rego RL, Foster N, et al. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 2006; 101:2818-25. (Pubitemid 44902656)
45. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131:729-37. (Pubitemid 44307064)
46. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-206. (Pubitemid 32319494)
47. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute- National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25:767-72. (Pubitemid 350002875)
48. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). In: American Society of Clinical Oncology Annual Meeting; 2009; Orlando, FL. J Clin Oncol 2009;27:abstr 4001.
49. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27:1814-21.
50. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57:941-50. (Pubitemid 351919529)
51. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41:2060-70. (Pubitemid 41337947)
52. Roth AD, Tejpar S, Yan P, et al. Correlation of molecular markers in colon cancer with stage-specific prognosis: results of the translational study on the PETACC 3 - EORTC 40993-SAKK 60-00 trial. In: Gastrointestinal Cancers Symposium; 2009; San Francisco, CA. 2009;abstr 288.
53. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34.
54. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65.
55. Van Cutsem E, Land I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. In: American Society of Clinical Oncology Annual Meeting 2008; Chicago, IL. J Clin Oncol 2008; 26:abstr 2.
56. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261-70.
57. Maughan TS, Adams R, Smith C, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. In: American Society of Clinical Oncology Annual Meeting; Chicago, IL; 2010.
58. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46:1997-2009.
59. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-12.
60. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30.
61. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101:715-21.
62. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62.
63. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361:98-9.
64. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. In: Gastrointestinal Cancers Symposium; 2010; Orlando, FL. 2010; abstr 281.
65. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466-74.
66. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91:355-8. (Pubitemid 39037083)
67. Ramos FJ, Capellà G, Tabernero JM, et al. Genomic profiling for prognosis prediction and KRas, BRaf, and Phosphatidylinositol-3-OH kinase (PI3K) mutations prediction in stage II and III colorectal cancer (CRC) patients (pts). In: Gastrointestinal Cancers Symposium; 2009; San Francisco, CA. 2009; abstr 337.
68. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58:90-6
69. NCCN Practice Guidelines in Oncology-v.1. 2009 Breast Cancer. National Comprehensive Cancer Network, 2009. http://www.nccn.org/professionals/physician- gls/recently-updated.asp. Accessed August 10, 2009.
70. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-312. (Pubitemid 350232263)
71. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8:R25.
72. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98:1183-92. (Pubitemid 44390989)
73. Garman KS, Acharya CR, Edelman E, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 2008; 105:19432-7.
74. Jiang Y, Casey G, Lavery IC, et al. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008; 10:346-54. (Pubitemid 352019121)
75. O'Connell MJ, Paik S, Yothers G, et al. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. In: American Society of Clinical Oncology Annual Meeting; 2006; Orlando, FL. J Clin Oncol 2006; abstr 3518.
76. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685-91. (Pubitemid 46630932)
77. Cavalieri D, Dolara P, Mini E, et al. Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. Oncol Res 2007; 16:535-48. (Pubitemid 351211326)
78. Croner RS, Förtsch T, Brückl WM, et al. Molecular signature for lymphatic metastasis in colorectal carcinomas. Ann Surg 2008; 247:803-10. (Pubitemid 351591515)
79. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526-35.
80. Munoz Llarena A Garcia A, Suarez B, et al. Gene expression profile of human colorectal cancer using oligonucleotide microarray. In: American Society of Clinical Oncology Annual Meeting; 2009; Orlando, FL. J Clin Oncol 2009; 27:abstr e22182.
81. Koehler A, Bataille F, Schmid C, et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 2004; 204:65-74. (Pubitemid 39214483)
82. Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009; 115:283-92.
83. Bandrés E, Malumbres R, Cubedo E, et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep 2007; 17:1089-94.
84. Johnston PG, Mulligan K, Kay E, et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) using a unique disease specific colorectal array. In: American Society of Clinical Oncology Annual Meeting; 2006. J Clin Oncol 2006; 24:abstr 3519.
85. Cascinu S, Zaniboni A, Scartozzi M, et al. Molecular biology for stage II colorectal cancer: the jury is still out. J Clin Oncol 2007; 25:2861, author reply 2862-3. (Pubitemid 47123203)
86. Lu AT, Salpeter SR, Reeve AE, et al. Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer 2009; 8:207-14.
87. Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007; 25:773-80. (Pubitemid 350002876)
88. Rosenberg R, Maak M, Simon I, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. In: Gastrointestinal Cancers Symposium 2011. San Francisco, CA, 2011.
89. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
90. O'Connell MJ, Lavery IC, Gray RG, et al. Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of 12-gene colon cancer recurrence score. In: Gastrointestinal Cancers Symposium; 2010; Orlando, FL. 2010; abstr 280.
91. Ray T. ASCO Studies Bolster Agendia's Marketing Plans for ColoPrint and MammaPrint. Pharmacogenomics Reporter 2009.